Drug intelligence / Profile preview

MT-3534

Development stage: Phase 1
Lead developer: Mitsubishi Tanabe Pharma
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

MT-3534 is an investigational antibody drug being developed by Mitsubishi Tanabe Pharma Corporation, in collaboration with Pharma Foods International, for the treatment of autoimmune diseases. It is currently in Phase 1 clinical trials in Japan, where it is being evaluated for safety, tolerability, and pharmacokinetics following intravenous administration to healthy volunteers. The precise mechanism of action has not been disclosed as of the latest updates. MT-3534 represents a new molecular entity and does not have orphan drug status.

Beyond the preview

Go deeper on MT-3534.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MT-3534.

Explore the full profile